Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for gliosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Jul 2022: Trial registered, NCT05465954
  2. 24 Jan 2023: Trial started, NCT05465954

The trials

NCT05465954: Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

State
Under way
Phase
Phase 2
People
53 taking part
Started
24 Jan 2023
Primary completion
2 Sep 2026
Arms
Treatment (efineptakin alfa, pembrolizumab)
Results
None posted
  1. 20 Jul 2022: Trial registered
  2. 24 Jan 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.